To date, β-lapachone and its derivatives are the most studied NQO1-bioactivatable quinones, and the molecular mechanisms by which they promote cytotoxicity have been thoroughly characterized [[20], [21], [22], [23], [24]] (Fig. 1A). NQO1 has been proposed as a target for NSCLC therapy, as it is overexpressed in lung tumors but not in adjacent normal tissues [[25], [26], [27]]. This evidence concerns the gene NQO1 and non-small cell lung carcinoma.